Share on StockTwits

The Advisory Board Company (NASDAQ:ABCO) CFO Michael T. Kirshbaum sold 2,625 shares of The Advisory Board Company stock on the open market in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $58.91, for a total value of $154,638.75. Following the completion of the sale, the chief financial officer now directly owns 22,309 shares of the company’s stock, valued at approximately $1,314,223. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

The Advisory Board Company (NASDAQ:ABCO) traded down 0.35% on Thursday, hitting $60.46. 139,453 shares of the company’s stock traded hands. The Advisory Board Company has a 52 week low of $44.20 and a 52 week high of $70.55. The stock’s 50-day moving average is $64.49 and its 200-day moving average is $63.. The company has a market cap of $2.185 billion and a price-to-earnings ratio of 102.83.

The Advisory Board Company (NASDAQ:ABCO) last released its earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.29 by $0.03. The company had revenue of $131.00 million for the quarter, compared to the consensus estimate of $132.58 million. During the same quarter last year, the company posted $0.28 earnings per share. The Advisory Board Company’s revenue was up 12.7% compared to the same quarter last year. Analysts expect that The Advisory Board Company will post $1.17 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of The Advisory Board Company in a research note on Tuesday. They now have a $68.00 price target on the stock. Separately, analysts at SunTrust initiated coverage on shares of The Advisory Board Company in a research note on Wednesday, April 9th. They set a “buy” rating and a $78.00 price target on the stock. Finally, analysts at Zacks upgraded shares of The Advisory Board Company from an “underperform” rating to a “neutral” rating in a research note on Wednesday, April 2nd. They now have a $66.00 price target on the stock. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $67.88.

The Advisory Board Companyprovides best practices research and analysis, software tools, and management and advisory services to the health care and education industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.